Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) EPS (Weighted Average and Diluted) (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of EPS (Weighted Average and Diluted) data on record, last reported at $0.51 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 31.08% year-over-year to $0.51; the TTM value through Dec 2025 reached $2.03, down 33.66%, while the annual FY2025 figure was $2.03, 33.66% down from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.51 in Q4 2025 per AMPH's latest filing, up from $0.37 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.91 in Q3 2023 and bottomed at $0.1 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.53, with a median of $0.51 recorded in 2025.
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 637.5% in 2021, then tumbled 52.56% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.4 in 2021, then soared by 62.5% to $0.65 in 2022, then grew by 6.15% to $0.69 in 2023, then rose by 7.25% to $0.74 in 2024, then tumbled by 31.08% to $0.51 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $0.51 in Q4 2025, $0.37 in Q3 2025, and $0.64 in Q2 2025.